drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T)
drug_description
Autologous chimeric antigen receptor T-cell therapy engineered to express an anti-CEACAM5 (CEA/CD66e) CAR; upon binding to CEA on tumor cells, CAR signaling activates T-cell cytotoxicity and cytokine release. Administered intravenously or intraperitoneally.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous, Intraperitoneal
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor targeting CEACAM5 (CEA). Upon binding CEA on tumor cells, CAR signaling (CD3ΞΆ with costimulatory domains) activates T-cell cytotoxicity, proliferation, and cytokine release, leading to perforin/granzyme-mediated killing of CEA-positive cells.
drug_name
CEA-targeted CAR T cells (anti-CEACAM5)
nct_id_drug_ref
NCT06768151